



## SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

*Presented by*

**Yale School of Medicine, Human and Translational Immunology Program**

# **“Novel and targetable immune checkpoint in Chronic Lymphocytic Leukemia (CLL)”**

**Fabienne Mackay, PhD, FAHMS**

**Director and CEO, QIMR Berghofer Medical Research Institute, Brisbane, Australia**

**Tuesday, June 1, 2021 from 4-5 PM**

**<https://yale.zoom.us/j/96238108557?pwd=bG9jaEhvMnNqZ1hGVkYrM2pGdGczUT09>**

**Password: HTI**

**Or by telephone: 203-432-9666**

**Meeting ID: 962 3810 8557**

**CME Activity Code: Text 22221 to 203-442-9435**

**Host: Dr. Joseph Craft**

**Course Directors: Dr. Carrie Lucas and Dr. Ellen Foxman**

*There is no corporate support for this activity. This activity is not supported by any educational grants.  
This course will fulfill the licensure requirement set forth by the State of Connecticut*

### **ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### **TARGET AUDIENCE**

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

### **NEEDS ASSESSMENT**

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

### **DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

### **LEARNING OBJECTIVES**

At the conclusion of this activity, participants will:

1. Understand the negative immune-suppressive impact of CLL leading to increased vulnerability to severe infectious diseases and inability to promote anti-tumor immunity
2. Understand the role of cytokines in promoting CLL
3. Understand that the immunosuppression is reversible when targeting the specific cytokine receptor TACI

### **FACULTY DISCLOSURES**

Fabienne Mackay: None  
Carrie Lucas: None  
Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.